Anti-CD20 antibodies

特許 権利維持 CD20 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. The anti-CD20 mAB Ofatumumab (Genmab) was approved by FDA in Oct 2009 for Chronic lymphocytic leukemia. Additional anti-CD20 antibody therapeutics under development (phase II or III clinical trials in 2008) include : AME-133v (by Applied Molecular Evolution), Ocrelizumab for multiple sclerosis (rheumatoid arthritis discontinued in 2010), TRU-015 (by Trubion), (discontinued in 2010[13]) IMMU-106 (veltuzumab).